$97.13 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) This Quarter
Brokerages predict that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) will report $97.13 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for…
From the Equity Insider archive. This article dates from Apr 11, 2022 and is preserved as first published.
Brokerages predict that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) will report $97.13 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Ironwood Pharmaceuticals’ earnings, with estimates ranging from $97.00 million to $97.26 million. Ironwood Pharmaceuticals reported sales of $88.85 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 9.3%. The company is scheduled to issue its next earnings results on Monday, January 1st.
On average, analysts expect that Ironwood Pharmaceuticals will report full-year sales of $434.03 million for the current fiscal year, with estimates ranging from $421.00 million to $447.06 million. For the next fiscal year, analysts forecast that the company will post sales of $487.25 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) last released its quarterly earnings data on Thursday, February 17th. The biotechnology company reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.04). The business had revenue of $117.13 million during the quarter, compared to the consensus estimate of $110.18 million. Ironwood Pharmaceuticals had a return on equity of 42.43% and a net margin of 127.72%. The business’s revenue was up .4% on a year-over-year basis. During the same period last year, the company earned $0.36 EPS.
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) last released its quarterly earnings data on Thursday, February 17th.
IRWD has been the subject of a number of recent analyst reports. TheStreet raised Ironwood Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Wednesday, January 19th. StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, April 1st. Two analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $14.33.
In other Ironwood Pharmaceuticals news, insider Ronald Silver sold 3,031 shares of the company’s stock in a transaction that occurred on Thursday, March 24th. The stock was sold at an average price of $12.75, for a total transaction of $38,645.25. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 12.60% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Norges Bank purchased a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter worth approximately $35,170,000. Barclays PLC raised its holdings in shares of Ironwood Pharmaceuticals by 3.0% in the fourth quarter. Barclays PLC now owns 222,204 shares of the biotechnology company’s stock worth $2,590,000 after buying an additional 6,488 shares during the period. BlackRock Inc. grew its stake in Ironwood Pharmaceuticals by 15.2% in the fourth quarter. BlackRock Inc. now owns 14,368,890 shares of the biotechnology company’s stock worth $167,541,000 after purchasing an additional 1,897,115 shares in the last quarter. Comerica Bank grew its stake in Ironwood Pharmaceuticals by 20.7% in the fourth quarter. Comerica Bank now owns 602,957 shares of the biotechnology company’s stock worth $6,717,000 after purchasing an additional 103,370 shares in the last quarter. Finally, California State Teachers Retirement System grew its stake in Ironwood Pharmaceuticals by 3.4% in the fourth quarter. California State Teachers Retirement System now owns 211,014 shares of the biotechnology company’s stock worth $2,460,000 after purchasing an additional 6,944 shares in the last quarter.
NASDAQ IRWD opened at $12.72 on Friday. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of 3.94 and a beta of 1.22. The company has a quick ratio of 4.61, a current ratio of 4.61 and a debt-to-equity ratio of 0.56. The business has a 50-day moving average price of $11.63 and a 200-day moving average price of $11.96. Ironwood Pharmaceuticals has a twelve month low of $10.02 and a twelve month high of $14.27.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.
